Lifecore Biomedical Files 8-K on Officer/Director Changes
Ticker: LFCR · Form: 8-K · Filed: Sep 23, 2024 · CIK: 1005286
| Field | Detail |
|---|---|
| Company | Lifecore Biomedical, Inc. \De\ (LFCR) |
| Form Type | 8-K |
| Filed Date | Sep 23, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, corporate-governance, filing
Related Tickers: LNDC
TL;DR
Lifecore Biomedical (LNDC) filed an 8-K today covering exec/director changes and compensation.
AI Summary
On September 23, 2024, Lifecore Biomedical, Inc. filed an 8-K report detailing changes in its board of directors and executive officers. The report also covers compensatory arrangements for certain officers and shareholder nominations. The company, formerly known as Landec Corp, is incorporated in Delaware and headquartered in Chaska, Minnesota.
Why It Matters
Changes in a company's board of directors and executive officers can signal shifts in strategy or governance, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in executive and board composition can introduce uncertainty regarding future strategy and operational stability.
Key Numbers
- 000-27446 — SEC File Number (Identifies the company's filing with the SEC.)
- 94-3025618 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Lifecore Biomedical, Inc. (company) — Registrant
- Landec Corp (company) — Former company name
- September 23, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Chaska, Minnesota (location) — Principal executive offices
FAQ
What specific changes were made to the board of directors or certain officers?
The filing indicates 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' as items reported, but the specific names and details of these changes are not provided in the excerpt.
What is the nature of the compensatory arrangements mentioned?
The filing lists 'Compensatory Arrangements of Certain Officers' as an item, but the details of these arrangements are not included in the provided text.
What is the significance of 'Shareholder Nominations Pursuant to Exchange Act Rule 14a-11'?
This indicates that the company is reporting on nominations made by shareholders under a specific SEC rule, likely related to director elections.
When was Lifecore Biomedical, Inc. formerly known as Landec Corp?
The date of the name change from Landec Corp to Lifecore Biomedical, Inc. was December 22, 1995.
What is Lifecore Biomedical's primary business classification?
The company is classified under 'Pharmaceutical Preparations [2834]' according to its Standard Industrial Classification.
Filing Stats: 772 words · 3 min read · ~3 pages · Grade level 14.1 · Accepted 2024-09-23 16:14:54
Filing Documents
- lndc-20240923.htm (8-K) — 28KB
- 0001005286-24-000138.txt ( ) — 149KB
- lndc-20240923.xsd (EX-101.SCH) — 2KB
- lndc-20240923_lab.xml (EX-101.LAB) — 21KB
- lndc-20240923_pre.xml (EX-101.PRE) — 12KB
- lndc-20240923_htm.xml (XML) — 3KB
08 Shareholder Director Nominations
Item 5.08 Shareholder Director Nominations. On September 23, 2024, the Board established November 7, 2024 as the date of the Annual Meeting. The Annual Meeting date, the record date for the Annual Meeting and detailed information regarding the proposals to be presented at the Annual Meeting will be set forth in the Company's Definitive Proxy Statement on Schedule 14A to be filed with the Securities and Exchange Commission ("SEC"). Since the Annual Meeting will take place more than 30 days from the anniversary of the Company's 2023 annual stockholder meeting (the "2023 Annual Meeting"), the due dates for the submission of any qualified shareholder proposal or qualified shareholder nominations under applicable SEC rules and our Amended and Restated Bylaws (the "Bylaws") listed in our Definitive Proxy Statement on Schedule 14A for the 2023 Annual Meeting, which was filed with the SEC on July 19, 2024, are no longer applicable. Such nominations or proposals, including pursuant to Rule 14a-8 or Rule 14a-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise, are now due to be received by the Company no later than October 3, 2024 and must comply with all of the applicable requirements set forth in the rules and regulations under the Exchange Act, the Bylaws and the applicable laws of the State of Delaware. Notices should be sent to the Company's Secretary at the following address: Lifecore Biomedical, Inc., Attn: Secretary, 3515 Lyman Blvd., Chaska, MN 55318. In addition to complying with this deadline, stockholder nominations or proposals intended to be considered for inclusion in the Company's proxy materials for the Annual Meeting must also comply with the Bylaws, all applicable rules and regulations promulgated by the SEC under the Exchange Act, including the additional requirements of Rule 14a-19(b) under the Exchange Act, and the applicable laws of the state of Delaware. SIGNATURE Pursuant to the requirements of the Securiti